← Back to Analyst Consensus 
RNTX Buy
Rein Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 12, 2026 (17 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 20, 2026 | Maxim Group | initiate | — → Buy | — | 42% |
| Jun 1, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jan 21, 2026 | Brookline Capital | downgrade | Buy → Hold | $0 | 38% |
| Sep 22, 2025 | HC Wainwright & Co. | initiate | — → Buy | $10 | 44% |
| Aug 19, 2025 | Brookline Capital | downgrade | Buy → Hold | $0 | 38% |
Price Target Trend
Apr 22, 2026 Latest: $6 Oct 22, 2026
EPS Estimates
0y $-0.46
Lo: $-0.47 Hi: $-0.45
2 analysts ▲1
0q $-0.10
Lo: $-0.10 Hi: $-0.10
2 analysts ▲1
+1y $-0.47
Lo: $-0.50 Hi: $-0.43
2 analysts ▲1
+1q $-0.13
Lo: $-0.15 Hi: $-0.10
2 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days